Part D Brand Discounts May Be More Useful In Catastrophic Phase, House Panel Told
Medicare Payment Advisory Commission executive director Mathews suggests at April 30 hearing that manufacturers should bear more “liability” for catastrophic coverage in Medicare Part D.
You may also be interested in...
Part D Cost Sharing Cap Offered In Draft US House Bill, But Not How To Pay For It
Biopharma manufacturers might not like the cost offsets that would cover the out-of-pocket maximum for patients in Medicare's drug program; committees seek comment on range of issues.
Capping Off The Rebate Debate: Will 2019 Price Push End With Co-Pay Cap?
The pharmaceutical industry and its strongest critics have long agreed on one thing: Medicare Part D would be improved if there was a cap on spending by beneficiaries. Now, there is an unlikely path that may make it surprisingly easy to get it done.
The Return Of The “Specialty” Drug Pricing Debate In The US
Pharma has been almost wholly successful in shifting the ground in the US drug pricing debate away from high-cost “specialty” products and towards the large gap between list and net prices, with the most intense focus on older medicines like insulin. What happens when the debate shifts back?